Although bioactivation is a well-documented process and the role of active metabolites in the drug discovery field has long been recognized, drug metabolites are usually ignored in virtual screening campaigns oriented to ...

Despite affecting around 8 million people worldwide and representing an economic burden above $7 billion/ year, currently approved medications to treat Chagas disease are still limited to two drugs, nifurtimox and benznidazole, ...

Drug repurposing involves finding new therapeutic uses for existing drugs, including marketed, discontinued, shelved, and investigational drugs. The advantages of this strategy are many: reduced drug development timeline, ...

In spite of remarkable advances in the knowledge on Trypanosoma cruzi biology, no medications to treat Chagas disease have been approved in the last 40 years and almost 8 million people remain infected. Since the public ...

Malaria is among the leading causes of death worldwide. The emergence of Plasmodium falciparum resistant strains with reduced sensitivity to the first line combination therapy and suboptimal responses to insecticides used ...

Abstract/Resumen: Trypanosoma cruzi and Plasmodium falciparum are the etiologic agents of Chagas disease and Malaria, respectively. Cysteine proteases play key roles in the pathogenesis and survival of these parasites, ...